Bernadette Connaughton
Director at Halozyme Therapeutics, Inc. (HALO)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $990K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 11SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 1,62640,418 held (−4%) | $102.80 | $167K | +7.4% |
| Jul 2SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 1,00042,669 held (−2%) | $76.40 | $76K | +44.5% |
| Jul 2SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 62542,044 held (−1%) | $77.21 | $48K | +43.0% |
| Jun 2SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 1,62543,669 held (−4%) | $66.21 | $108K | +66.8% |
| May 5SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 1,62538,498 held (−4%) | $63.48 | $103K | +73.9% |
| Jan 6SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 2,00040,123 held (−5%) | $70.25 | $140K | +57.2% |
| Dec 1SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 82942,123 held (−2%) | $71.60 | $59K | +54.2% |
| Nov 12SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 2,00042,952 held (−4%) | $68.48 | $137K | +61.2% |
| Oct 1SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 1,50045,452 held (−3%) | $75.09 | $113K | +47.1% |
| Oct 1SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 50044,952 held (−1%) | $75.70 | $38K | +45.9% |
- Sell
Director Bernadette Connaughton sold $167K of HALO at $102.80 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Bernadette Connaughton sold $76K of HALO at $76.40 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Bernadette Connaughton sold $48K of HALO at $77.21 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Bernadette Connaughton sold $108K of HALO at $66.21 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Bernadette Connaughton sold $103K of HALO at $63.48 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Bernadette Connaughton sold $140K of HALO at $70.25 — pre-scheduled 10b5-1 plan sale.